Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov.

Literature DB >> 32730617

Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov.

Krishna Pundi¹, Alexander C Perino¹, Robert A Harrington¹, Harlan M Krumholz², Mintu P Turakhia¹.

Abstract

Entities: Disease

Mesh：

Year: 2020 PMID： 32730617 PMCID： PMC7385669 DOI： 10.1001/jamainternmed.2020.2904

Source DB: PubMed Journal: JAMA Intern Med ISSN： 2168-6106 Impact factor: 21.873

× No keyword cloud information.

3 in total

1. Studies registered in non-ClinicalTrials.gov accounted for an increasing proportion of protocol registrations in medical research.

Authors: Masahiro Banno; Yasushi Tsujimoto; Yuki Kataoka
Journal: J Clin Epidemiol Date: 2019-09-12 Impact factor: 6.437

2. Flooded by the torrent: the COVID-19 drug pipeline.

Authors: Asher Mullard
Journal: Lancet Date: 2020-04-18 Impact factor: 79.321

3. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.

Authors: Alfred H J Kim; Jeffrey A Sparks; Jean W Liew; Michael S Putman; Francis Berenbaum; Alí Duarte-García; Elizabeth R Graef; Peter Korsten; Sebastian E Sattui; Emily Sirotich; Manuel F Ugarte-Gil; Kate Webb; Rebecca Grainger
Journal: Ann Intern Med Date: 2020-03-30 Impact factor: 25.391

3 in total

19 in total

1. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.

Authors: Jessica M Franklin; Elisabetta Patorno; Rishi J Desai; Robert J Glynn; David Martin; Kenneth Quinto; Ajinkya Pawar; Lily G Bessette; Hemin Lee; Elizabeth M Garry; Nileesa Gautam; Sebastian Schneeweiss
Journal: Circulation Date: 2020-12-17 Impact factor: 29.690

Review 2. Ten tips for improving your clinical practice during the COVID-19 pandemic.

Authors: Elissa M Abrams; Alexander G Singer; Matthew Greenhawt; David Stukus; Marcus Shaker
Journal: Curr Opin Pediatr Date: 2021-04-01 Impact factor: 2.893

Review 3. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.

Authors: Azita H Talasaz; Parham Sadeghipour; Hessam Kakavand; Maryam Aghakouchakzadeh; Elaheh Kordzadeh-Kermani; Benjamin W Van Tassell; Azin Gheymati; Hamid Ariannejad; Seyed Hossein Hosseini; Sepehr Jamalkhani; Michelle Sholzberg; Manuel Monreal; David Jimenez; Gregory Piazza; Sahil A Parikh; Ajay J Kirtane; John W Eikelboom; Jean M Connors; Beverley J Hunt; Stavros V Konstantinides; Mary Cushman; Jeffrey I Weitz; Gregg W Stone; Harlan M Krumholz; Gregory Y H Lip; Samuel Z Goldhaber; Behnood Bikdeli
Journal: J Am Coll Cardiol Date: 2021-03-11 Impact factor: 24.094

10. How the clinical research community responded to the COVID-19 pandemic: an analysis of the COVID-19 clinical studies in ClinicalTrials.gov.

Authors: Zhe He; Arslan Erdengasileng; Xiao Luo; Aiwen Xing; Neil Charness; Jiang Bian
Journal: JAMIA Open Date: 2021-04-20

Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov.

1. Studies registered in non-ClinicalTrials.gov accounted for an increasing proportion of protocol registrations in medical research.

2. Flooded by the torrent: the COVID-19 drug pipeline.

3. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.

1. Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative.

Review 2. Ten tips for improving your clinical practice during the COVID-19 pandemic.

Review 3. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review.

4. Medication Use Among Patients With COVID-19 in a Large, National Dataset: Cerner Real-World Data™.

5. Assessment of COVID-19-related meta-analysis reporting quality.

Review 6. Implications of the COVID-19 Pandemic for Cardiovascular Disease and Risk-Factor Management.

Review 7. Anticipating the long-term cardiovascular effects of COVID-19.

Review 8. Repurposing anticancer drugs for the management of COVID-19.

9. Inflection Point: Ideas for Accelerating Breakthroughs and Improving Cardiovascular Health.

10. How the clinical research community responded to the COVID-19 pandemic: an analysis of the COVID-19 clinical studies in ClinicalTrials.gov.